By Ahmed Aboulenein WASHINGTON (Reuters) -Current laws and regulations are not enough to protect Americans from the risks of ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Nearly 70% of adults in Indiana are classified as overweight or obese, contributing to a broader health crisis in the United ...